Beam Therapeutics Stock Price, News & Analysis (NASDAQ:BEAM)

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Beam Therapeutics in the last year. There are currently 6 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" BEAM shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BEAM, but not buy additional shares or sell existing shares.
View BEAM analyst ratings or view top-rated stocks.

11 brokerages have issued twelve-month price targets for Beam Therapeutics' shares. Their BEAM share price targets range from $20.00 to $105.00. On average, they expect the company's share price to reach $48.80 in the next twelve months. This suggests a possible upside of 72.7% from the stock's current price.
View analysts price targets for BEAM or view top-rated stocks among Wall Street analysts.

Beam Therapeutics' stock was trading at $39.11 at the beginning of the year. Since then, BEAM shares have decreased by 27.8% and is now trading at $28.25.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024.
View our BEAM earnings forecast.

Beam Therapeutics Inc. (NASDAQ:BEAM) issued its quarterly earnings results on Wednesday, November, 8th. The company reported ($1.22) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.33) by $0.11. The business earned $17.20 million during the quarter, compared to analysts' expectations of $17.09 million. Beam Therapeutics had a negative trailing twelve-month return on equity of 40.66% and a negative net margin of 384.62%. The company's revenue was up 8.9% compared to the same quarter last year. During the same period in the previous year, the company posted ($1.56) EPS.

ETFs with the largest weight of Beam Therapeutics (NASDAQ:BEAM) stock in their portfolio include Kelly CRISPR & Gene Editing Technology ETF (XDNA), Global X Genomics & Biotechnology ETF (GNOM), iShares Genomics Immunology and Healthcare ETF (IDNA), ARK Genomic Revolution ETF (ARKG), ARK Innovation ETF (ARKK), Horizon Kinetics Medical ETF (MEDX), Jacob Forward ETF (JFWD) and WisdomTree BioRevolution Fund (WDNA).

Based on aggregate information from My MarketBeat watchlists, some companies that other Beam Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Editas Medicine (EDIT), Cisco Systems (CSCO), Block (SQ), Skyworks Solutions (SWKS), Akoustis Technologies (AKTS), Invitae (NVTA), QUALCOMM (QCOM) and Alector (ALEC).

(BEAM) raised $101 million in an initial public offering (IPO) on Thursday, February 6th 2020. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Jefferies and Barclays served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Beam Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include ARK Investment Management LLC (11.09%), FMR LLC (7.97%), Sumitomo Mitsui Trust Holdings Inc. (2.07%), Redmile Group LLC (1.80%), Baillie Gifford & Co. (1.07%) and JPMorgan Chase & Co. (0.81%). Insiders that own company stock include Amy Simon, Christine Bellon, Fmr Llc, Giuseppe Ciaramella, Graham K Cooper, John M Evans, John M Evans and Terry-Ann Burrell.
View institutional ownership trends.

Shares of BEAM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.